Haleon (HLN) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
30 Jul, 2026Executive summary
Achieved 2.6% organic revenue growth in H1 2026, with Q2 sequential improvement to 3.1%, driven by balanced price and volume/mix and strong performance in North America, China, and India.
73% of the business gained or maintained market share, reflecting competitive strength despite challenging consumer environments.
Adjusted operating profit grew 8.2% at constant currency, supported by gross margin expansion and productivity initiatives.
Adjusted diluted EPS grew 12.0% at AER, supported by robust free cash flow generation of £769m.
FY 2026 guidance maintained for 3–5% organic revenue growth and high single-digit adjusted operating profit growth.
Financial highlights
H1 2026 revenue reached £5.6bn, up 2.2% reported and 2.6% organic year-over-year.
Adjusted gross profit rose 4.7% at constant currency, with margin up 140bps to 66.5%.
Adjusted operating profit increased 8.2% at constant currency, margin up 120bps to 24.3%.
Adjusted diluted EPS: 10.3p (up 12.0%); free cash flow: £769m (+£35m YoY).
Net debt/Adjusted EBITDA improved to 2.5x, with net debt at £7.5bn as of June 2026.
Outlook and guidance
FY 2026 guidance reaffirmed: 3–5% organic revenue growth and high single-digit adjusted operating profit growth.
Medium-term targets: 4–6% annual organic revenue growth, high single-digit adjusted operating profit growth, and net debt/Adjusted EBITDA around 2.5x.
Dividend expected to grow at least in line with adjusted earnings.
Latest events from Haleon
- Q1 2025 organic revenue up 3.5%, with FY 2025 guidance reaffirmed at 4-6% growth.HLN
Q1 2025 TU9 Jul 2026 - Strong organic profit growth and margin expansion, led by EMEA & APAC, offset US weakness.HLN
H1 20259 Jul 2026 - Q1 2026 organic revenue up 2.2%, driven by Oral Health and innovation, with FY guidance reaffirmed.HLN
Q1 2026 TU8 Jul 2026 - Q3 organic revenue rose 3.4%, driven by Oral Health, VMS, and robust global execution.HLN
Q3 2025 TU8 Jul 2026 - Q3 organic revenue up 6.1%, profit up 7.4%, with margin expansion and guidance reaffirmed.HLN
Q3 2024 TU8 Jul 2026 - Growth, productivity, and innovation drive margin gains and portfolio shift to high-growth health categories.HLN
23rd annual dbAccess Global Consumer Conference3 Jun 2026 - Gross margin rose 220 bps as profit and shareholder returns grew, despite U.S. and cold/flu softness.HLN
H2 2025 (Q&A)25 Feb 2026 - 3% organic growth, 10.5% profit growth, and strong shareholder returns in 2025.HLN
H2 202525 Feb 2026 - Oral health and emerging markets offset U.S. softness as savings and innovation drive growth.HLN
Barclays 18th Annual Global Consumer Staples Conference 20253 Feb 2026